Nagio Takigawa

Pseudoprogression of Lung Cancer after Concomitant Chemoradiotherapy (2008)

Ichihara, Eiki, Kiura, Katsuyuki, Takigawa, Nagio, Omori, Masako, Aoe, Motoi, Tanimoto, Mitsune, ...

We observed re-enlargement of a squamous cell carcinoma without recurrence. The tumour regressed markedly after concomitant chemoradiotherapy, but within 1 month, we supposed that the tumour had...

Aberrant promoter hypermethylation in serum DNA from patients with silicosis (2008)

Umemura, Shigeki, Fujimoto, Nobukazu, Hiraki, Akio, Gemba, Kenichi, Takigawa, Nagio, Fujiwara, Keiichi, ...

It is well established that patients with silicosis are at high risk for lung cancer; however, it is difficult to detect lung cancer by chest radiography during follow-up treatment of patients with...

Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line (2007)

Matsuo, Keisuke, Kiura, Katsuyuki, Ueoka, Hiroshi, Tabata, Masahiro, Shibayama, Takuo, Matsumura, Tadashi, ...

We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overexpression of...

Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. (2007)

Yonei, Toshiro, Ohnoshi, Taisuke, Hiraki, Shunkichi, Ueoka, Hiroshi, Kiura, Katsuyuki, Moritaka, Tomonori, ...

Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from...

Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. (2007)

Takigawa, Nagio, Ohnoshi, Taisuke, Ueoka, Hiroshi, Kiura, Katsuyuki, Kimura, Ikuro

In an attempt to predict the clinical activity of newly developed anthracycline analogues, ME2303, KRN8602, and SM5887 in the treatment of lung cancer, we compared antitumor activity of these drugs...

Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. (2007)

Takigawa, Nagio, Ohnoshi, Taisuke, Ueoka, Hiroshi, Kiura, Katsuyuki, Kimura, Ikuro

An etoposide-resistant subline, SBC-3/ETP, from a human small cell lung cancer cell line, SBC-3, was developed by continuous exposure to increasing concentrations of etoposide in culture. The...

Severe Interstitial Pneumonia Induced by Paclitaxel in a Patient with Adenocarcinoma of the Lung (2006)

Suzaki, Noriyuki, Hiraki, Akio, Takigawa, Nagio, Ueoka, Hiroshi, Tanimoto, Yasushi, Kozuki, Toshiyuki, ...

A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second...

Daily low-dose cisplatin and concurrent thoracic irradiation for poor-risk patients with unresectable non-small-cell lung cancer. (2006)

Takata, Ichiro, Ueoka, Hiroshi, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, Katayama, Hideki, ...

A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cisplatin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer (NSCLC)....

Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. (2006)

Kawada, Kazuhiko, Yonei, Toshiro, Ueoka, Hiroshi, Kiura, Katsuyuki, Tabata, Masahiro, Takigawa, Nagio, ...

When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the...

Prognostic Factors in Advanced Non-small Cell Lung Cancer: Elevated Serum Levels of Neuron Specific Enolase Indicate Poor Prognosis (2000)

Maeda, Tadashi, Ueoka, Hiroshi, Tabata, Masahiro, Kiura, Katsuyuki, Shibayama, Takuo, Gemba, Kenichi, ...

Background: Non-small cell lung cancer (NSCLC) is resistant to chemotherapy and prognosis of advanced NSCLC patients is considered to be dependent on various prognostic factors. Methods: We analyzed...